Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 6/20 | 0.73 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.73 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25287166 | 1.00 | PIM1 (0.73) | PIM1PIM2PIP4K2ANPC1RAB9A | |
| SCHEMBL2541053 | 0.85 | PIM1 (1.00) | PIM1PIM2NPC1RAB9APTPN1 | |
| SCHEMBL2541054 | 0.85 | PIM1 (1.00) | PIM1PIM2NPC1RAB9APTPN1 | |
| SCHEMBL2541051 | 0.85 | PIM1 (1.00) | PIM1PIM2NPC1RAB9APTPN1 | |
| SCHEMBL25285660 | 0.85 | PIM1 (0.71) | PIM1PIM2NPC1RAB9AHTT | |
| SCHEMBL25243027 | 0.85 | PIM1 (0.71) | PIM1PIM2NPC1RAB9AHTT | |
| SCHEMBL25242946 | 0.84 | PIM1 (0.70) | PIM1PIM2PIP4K2ANPC1RAB9A | |
| SCHEMBL25289662 | 0.84 | PIM1 (0.70) | PIM1PIM2PIP4K2ANPC1RAB9A | |
| SCHEMBL25286252 | 0.80 | PIM1 (0.65) | PIM1PIM2NPC1RAB9AHTT | |
| SCHEMBL25286253 | 0.80 | PIM1 (0.65) | PIM1PIM2NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023121184-A1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME | (주)메디픽 | 2023-06-29 | — | — | WO | claimed |
| US-20250066347-A1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME | MEDIFIC, INC. (KR) | 2025-02-27 | — | — | US | disclosed |
| EP-4455143-A1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME | Medific, Inc. (KR) | 2024-10-30 | — | — | EP | disclosed |
| CN-118591539-A | Substituted thiazolidinedione derivative compounds and pharmaceutical composition for preventing or treating cancer comprising the same | (株)美迪菲 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023121184-A1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME | (주)메디픽 | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066347-A1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME | SREBF1, SREBF2, SP1 | PIM1 922/4885PIM2 1740/4885PIP4K2A 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.